HK Stock Market Move | BOAN BIOTECH (06955) rose more than 3% in the morning. Recently, the application for market authorization of Aflibercept intravitreal injection has been submitted in Brazil.

BOAN BIOTECH (06955) rose over 3% in the morning, and as of the time of writing, it has increased by 2.76%, trading at HKD 4.84, with a transaction volume of HKD 10.1045 million. In terms of news, recently, BOAN BIOTECH announced that the application for market authorization of its Abicipar injection solution (BA9101) has been submitted to Brazil's National Health Surveillance Agency (ANVISA). This product is intended for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). BA9101 is a biosimilar to EYLEA, which has been approved for sale in China as of November 2025 (Chinese product name: ). As one of the company's key products implementing its global development strategy, BA9101's overseas expansion is accelerating. In June 2025, the company signed an exclusive licensing cooperation agreement for overseas markets with Shenzhen Kexing Pharmaceuticals, a wholly-owned subsidiary of Kexing Biopharm, granting it exclusive rights to sell BA9101 in all countries and regions except for mainland China, the EU, the UK, the US, and Japan. Currently, the product's registration and market launch in the relevant regions are progressing as planned.